Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products
The four latest products to be accepted onto the European Medicines Agency’s popular priority medicines scheme target mantle cell lymphoma, chikungunya, hematopoietic stem cell transplant patients, and the rare monogenic disease, X-linked myotubular myopathy.
